Nipent
information and resources from the National Cancer Institute
NCI Thesaurus | Nipent
(Other name for: pentostatin)NCI Thesaurus | Nipent
(Other name for: pentostatin)
pentostatin
Single agent treatment for adult patients with alpha interferon refractory hairy cell leukemia.
Parke-Davis Pharmaceutical Co. Oct 11 1991
pentostatin
Single-agent treatment for untreated hairy cell leukemia patients with active disease as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. (Supplement for front -line therapy.)
Parke-Davis Pharmaceutical Co. Sep 29 1993
|
|
|
|
news articles
Pentostatin, Cyclophosphamide, Rituxan® Active in Chronic ... Mar 10, 2006
Cancer Consultants (press release), ...published in the Journal of Clinical Oncology, the treatment combination consisting of the chemotherapy agents pentostatin (Nipent®), cyclohpsophamide (Cytoxan ...
SuperGen Announces Results From Combination Study in CLL Published ... Mar 14, 2006
PR Newswire (press release), SuperGen's product portfolio includes: Nipent(R) (pentostatin for injection); Mitomycin (generic brand of Mutamycin(R)); and SurfaceSafe(R) cleaner. ...
SuperGen Announces Results From Combination Study in CLL Published ... Mar 14, 2006
DG News Nipent(R) (pentostatin for injection) is currently approved as a single- agent treatment for patients with hairy cell leukemia and is not approved as either a ...
SUPG: Nipent Studies Presented at ASH Dec 9, 2005
PharmaLive.com (press release), DUBLIN, Calif., December 9, 2005 - SuperGen, Inc. (Nasdaq: SUPG) announced that abstracts from five studies of its anticancer drug Nipent® (pentostatin for ...
Studies of Nipent in Combination Cancer Therapies for Treatment of ... Dec 9, 2005
PharmaLive.com (press release), ...announced that abstracts from five studies of its anticancer drug Nipent(R) (pentostatin for injection) will be presented this week during the proceedings of ...
Studies of Nipent(R) in Combination Cancer Therapies for Treatment ... Dec 9, 2005
PR Newswire (press release), 9 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG) announced that abstracts from five studies of its anticancer drug Nipent(R) (pentostatin for injection ...
Studies of Nipent(R) in Combination Cancer Therapies for Treatment ... Dec 12, 2005
Drug Newswire (press release), DUBLIN, Calif. — SuperGen, Inc. (NASDAQ:SUPG) announced that abstracts from five studies of its anticancer drug Nipent(R) (pentostatin for injection) will be ...
Nipent®/Cytoxan®/Rituxan® Shows High Activity in High-Risk ... Nov 23, 2005
Cancer Consultants (press release), Researchers from Ohio State University and the Mayo Clinical have reported that the treatment combination consisting of Nipent (pentostatin), Cytoxan ...
Dacogen(TM) (Decitabine) Injection Complete Response Accepted for ... Dec 15, 2005
Genetic Engineering News, ...portfolio includes Orathecin(TM) (rubitecan) capsules, an investigational drug being evaluated for the treatment of pancreatic cancer; Nipent(R) (pentostatin ...
Dacogen(TM) (Decitabine) Injection Complete Response Accepted for ... Dec 15, 2005
Yahoo! News (press release) ...includes Orathecin(TM) (rubitecan) capsules, an investigational drug being evaluated for the treatment of pancreatic cancer; Nipent® (pentostatin for injection ...
Sports stores hit with large settlement Dec 9, 2005
San Jose Mercury News, ...(SUPG) plans to present abstracts for five of its studies on its anti-cancer drug Nipent at the 47th American Society Hematology annual meeting in Atlanta. ...
East Bay biz buzz: TSA Stores pays part of settlement Dec 10, 2005
Contra Costa Times, Fremont-based SuperGen Inc. (SUPG) said Friday it plans to present abstracts for five of its studies on its anti-cancer drug Nipent at the 47th American ...
(PRN) - MathStar Announces New Management Team and Addition of ... Dec 9, 2005
Bolsamania.com, ...[+]. (PRN) - Studies of Nipent(R) in Combination Cancer Therapies for Treatment of Chronic Lymphocytic Leukemia and Graft-versus Host Disease (GVHD) Presented ...
SuperGen to Present at First Albany Capital Annual Growth ... Dec 5, 2005
PR Newswire (press release), SuperGen's product portfolio includes Nipent(R) (pentostatin for injection); Mitomycin (generic brand of Mutamycin(R)); and SurfaceSafe(R) cleaner. ...
|
|
